Bone Is Alive: Remodeling, Osteoblasts & Osteoclasts

A skeleton under constant renovation

It is tempting to picture the skeleton as finished — laid down in childhood, then static. The truth is the opposite. Bone is torn down and rebuilt continuously through a process called bone remodeling, so that you replace roughly a tenth of your skeleton every year. This constant turnover repairs the tiny cracks of daily use, lets bone adapt its shape to the loads you put on it, and — crucially for us — keeps a calcium bank that the body can draw on.

Two cell types do the work, with opposite jobs. The osteoblast is the builder: it lays down new collagen matrix and helps it mineralize into hard bone. The osteoclast is the demolition crew: a large multinucleated cell that dissolves bone mineral and digests the matrix, a process called bone resorption. In a healthy adult their work is balanced — what osteoclasts remove, osteoblasts replace — so bone mass holds steady.

The RANKL switch — how PTH speaks to bone

Here is the surprise from the PTH guide, now explained. PTH cannot tell the osteoclast anything directly — osteoclasts have no PTH receptors. Instead PTH lands on the *builder*, the osteoblast, and tells it to display a signal molecule called RANKL on its surface. RANKL is the “grow up and start digging” command for osteoclast precursors. So the build cells issue the order that activates the demolition cells.

The osteoblast also makes a decoy protein, osteoprotegerin, that mops up RANKL before it can act — a built-in off-switch. Bone resorption is set by the *balance* of RANKL versus its decoy. This is not just textbook detail: the osteoporosis drug denosumab is an antibody that blocks RANKL, freezing the demolition crew in place. Understanding the switch lets you understand the drug.

PTH commands bone — the indirect route

  PTH (continuous, high)
     |
     v
  OSTEOBLAST  --displays-->  RANKL
     |                         |
     | also makes              | binds receptor on
     v   decoy (OPG)           v
   OPG ---soaks up---> RANKL   osteoclast precursor
                               |
  net RANKL signal -----------> matures into
                               active OSTEOCLAST
                               |
                               v
                       BONE RESORPTION
                       Ca + phosphate -> blood

Drug note: denosumab blocks RANKL -> resorption stops.

PTH never touches the osteoclast directly; it works through the osteoblast's RANKL signal, balanced by a decoy.

When the balance tips

Healthy bone keeps building and demolition matched. Tip the balance toward resorption and bone mass falls. *Continuously* high PTH does exactly this — it keeps RANKL switched on, so osteoclasts win and bone thins. The same losing balance, from a different cause, is osteoporosis. On the other side, calcitriol supports building by supplying the calcium and phosphate the osteoblast needs to mineralize new matrix; without enough, the matrix is laid down but stays soft.